#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Perspectives in Surgery / 2020 - 9

Circulating matrix metaloproteinases as biomarkers in colorectalcancer

Czech version

Authors: M. Čurillová 1;  M. Karlíková 2;  V. Karnos 1;  O. Topolčan 2
Authors‘ workplace: Chirurgické oddělení Fakultní nemocnice Plzeň a Lékařská fakulta v Plzni, Univerzita Karlova 1;  Oddělení imunochemické diagnostiky Fakultní nemocnice Plzeň 2
Published in: Rozhl. Chir., 2020, roč. 99, č. 9, s. 384-390.
Category: Review
doi: https://doi.org/10.33699/PIS.2020.99.9.384–390

Overview

The aim of this research is to offer comprehensive point of view related to perspective tumor markers called matrix metaloproteinases and their natural tissue inhibitors. Those markers are potentially useable mainly in postoperative follow-up in patients with colorectal cancer.

Keywords:

colorectal carcinoma – matrix metaloproteinases – serum biomarkers

Sources
  1. Ústav zdravotnických informací a statistiky ČR: Národní onkologický registr (NOR) (6. 5. 2020).
  2. Dušek L, Májek O, Mužík J, et al. Epidemiologie a populační screening nádorů tlustého střeva a konečníku v České republice na podkladě nově dostupných dat. Gastroent Hepatol. 2015;69(6):509–517. doi:10.14735/amgh2015509.
  3. Laronha H, Caldeira J. Structure and function of human matrix metalloproteinases. Cells 2020;9(5):1076. doi:10.3390/cells9051076.
  4. Johnson J. Matrix metalloproteinases and their inhibitors in cardiovascular pathologies: current knowledge and clinical potential. Metalloproteinases In Medicine 2014;1:21−36. doi.org/10.2147/MNM.S50999.
  5. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2(3):161−174. doi:10.1038/nrc745.
  6. Rodríguez D, Morrison CJ, Overall CM. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomic. Biochim Biophys Acta 2010;1803(1):39−54. doi:10.1016/j.bbamcr.2009.09.015.
  7. Quintero FS, Arreola R, Becerril-Villanueva E, et al. Role of matrix metalloproteinases in angiogenesis and cancer. Front Oncol .2019;9:1370. doi:10.3389/fonc.2019.01370.
  8. Stetler-Stevenson WG. The tumor microenvironment: Regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2. Cancer Metastasis Rev. 2008;27:57–66. doi: 10.1007/s10555-007-9105-8.
  9. Dao Thi MU, Trocmé C, Montmasson MP, et al. Investigating metalloproteinases MMP-2 and MMP-9 mechanosensitivity to feedback loops involved in the regulativ of in vitro angiogenesis by endogenous mechanical stresses. Acta Biother. 2012;60:21–40. doi: 10.1007/s10441-012-9147-3.
  10. Van Kempelen LCL, de Visser KA, Coussens LM. Inflammation, proteases and cancer. Eur J Cancer 2006;42:728–734.
  11. Stetler-Stevenson WG. The tumor microenvironment: Regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2. Cancer Metastasis Rev. 2008;27:57–66. doi: 10.1007/s10555-007-9105-8.
  12. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBSJ 2011;278(1):16−27. doi:10.1111/j.1742-4658.2010.07919.x.
  13. Fullár A, Kovalszky I, Bitsche M, et al. Tumor cell and carcinoma-associated fibroblast interaction regulates matrix metalloproteinases ant their inhibitors in oral squamous cell carcinoma. Exp Cell Res. 2012;318:1517–1527. doi: 10.1016/j.yexcr.2012.03.023.
  14. Sharma R, Chattopadhyay TK, Mathur M, et al. Prognostic significance of stromelysin-2 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer. Oncology 2004;67:300–309. doi: 10.1159/000081331.
  15. Liu H Q, Song S, Wang JH, et al. Expression of MMP-3 and TIMP-3 in gastric cancer tissue and its clinical significance. Oncol Lett. 2011;2:1319–1322. doi: 10.3892/ol.2011.399.
  16. Joergensen MT, Brünner N, de Muckadell OB. Comparison of circulating MMP-9, TIMP-1 and CA-19-9 in the detection of pancreatic cancer. Anticancer Res. 2010;30:587–592.
  17. Gao ZH, Tretiakova MS, Liu WH, et al. Association of E-cadherin, matrix metalloproteinases with the progression and metastasis of hepatocellular carcinoma. Mod Pathol. 2006;19:533–540. DOI: 10.1038/modpathol.3800554.
  18. Herszényi L, Hritz I, Pregun I, et al. Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in the esophageal carcinogenesis. World J Gastroenterol. 2007;13:676–682. doi: 10.3748/wjg.v13.i5.676.
  19. Herszényi L, Sipos F, Galamb O, et al. Matrix metalloproteinase-9 expression in the normal mucosa-adenoma-dysplasia-adenocarcinoma sequence of the colon. Pathol Oncol Res. 2008;14:31–37. doi: 10.1007/s12253-008-9004-5.
  20. Bendardaf R, Buhmeida A, Hilska M, et al. MMP-9 (gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients. Cancer Invest. 2010;1:38–43. doi: 10.3109/07357900802672761.
  21. Chu D, Zhao Z, Li Y, et al. Matrix metalloproteinase-9 is associated with relapse and prognosis of patients with colorectal cancer. Ann Surg Oncol. 2012;19:318–325. doi: 10.1245/s10434-011-1686-3.
  22. Langers AMJ, Verspaget HW, Hawinkels LJAC, et al. MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients. Br J Cancer 2012;106:1495–1498. doi: 10.1038/bjc.2012.80.
  23. Tomita T, Iwata K. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas-adenocarcinomas. Dig Colon Rectum. 1996;39:1255–1264. doi: 10.1007/BF02055119.
  24. Mroczko B, Groblewska M, Okulczyk B, et al. The diagnostic value of matrix matalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients. Int J Colorectal Dis. 2010;25:1177–1184. doi:10.1007/s00384-010-0991-9.
  25. Wilson S, Damery S, Stocken DD, et al. Serum matrix metalloproteinase 9 and colorectal neoplasia: A community-based evaluation of a potential diagnostic test. Br J Cancer 2012;106:1431–1438. doi: 10.1038/bjc.2012.93.
  26. Nielsen H J, Brünner N, Jorgensen L N, et al. Plasma TIMP-1 and CEA in detection of primary colorectal cancer: A prospective, population based study of 4509 high-risk individuals. Scand J Gastroenterol. 2011;46:60–69. doi: 10.3109/00365521.2010.513060.
  27. Hurst NG, Stocken DD, Wilson S, et al. Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer 2007;97:971–977. doi: 10.1038/sj.bjc.6603958.
  28. Hurst NG, Stocken DD, Wilson S, et al. Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer 2007;97:971–977. doi: 10.1038/sj.bjc.6603958.
  29. Hritz I, Varga MZ, Juhász M, et al. Increased serum MMP-2, MMP-7, MMP-9, TIMP-1 and TIMP-2 levels in colorectal cancer development. Gastroenterology 2011;140:S-343. doi: 10.1016/S0016-5085(11)61393-0.
  30. Min BS, Kim NK, Jeong HC, et al. High levels of serum VEGF and TIMP-1 are correlated with colon cancer liver metastasis and intrahepatic recurrence after liver resection. Oncol Lett. 2012;4:123–130. doi: 10.3892/ol.2012.691.
  31. Bourboulia D, Jensen-Taubman S, Rittler MR, et al. Endogenous angiogenesis inhibitor blocks tumor growth via direct and indirect effects on tumor microenvironment. Am J Pathol. 2011;179:2589–2600. doi: 10.1016/j.ajpath.2011.07.035.
  32. Murphy FR, Issa R, Zhou X, et al. Inhibition of apoptosis of activated hepatic stelete cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibitor: Implcations for reversibility of liver fibrosis. J Biol Chem. 2002;277:11069–11076. doi: 10.1074/jbc.M111490200.
  33. Alduaymi B, Christensen IJ, Sölétormos G, et al. Changes in soluble CEA and TIMP-1 levels during adjutant chemotherapy for stage III coloncancer. Anticancer Res. 2010;30:233–237.
  34. Jonsson A, Hjalmarsson C, Falk P, et al. Levels of matrix metalloproteinases differ in plasma and serum – aspects regarding analysis of biological markers in cancer. Br J Cancer 2016;115(6):703−706. doi: 10.1038/bjc.2016.127.
  35. Jonsson A, Hjalmarsson C, Falk P, et al. Stability of matrix metalloproteinase-9 as biological marker in colorectal cancer. Med Oncol. 2018;35(4):50. doi:10.1007/s12032-018-1109-4.
Labels
Surgery Orthopaedics Trauma surgery
Je nutné zjišťovat dopady covidu-19 na chirurgická pracoviště?
Recommendations for patient management after manual reduction of incarcerated inguinal hernia: a literature review
Changes in normothermia during surgery
Surgical treatment of extensive perianal hidradenitis
Incarcerated lumbar hernia in the Petit´s triangle as a cause of large bowel obstruction
Liver transplantation using grafts from donors after circulatory death – the first Czech Republic experience
Extensive bile duct injury resulting from a laparoscopic cholecystectomy resolved by a Roux-en-Y tri-hepaticojejunostomy: a case report
Article was published in

Perspectives in Surgery

Issue 9
2020 Issue 9
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#